Influence of EGFR-TKIs Treatment Lines and PFS on the Emergence of T790M Mutation

被引：0
|
作者：
Dong, X. [1 ]
Jia, W. [2 ]
Gu, D. [2 ]
Guo, R. [3 ]
Miao, L. [4 ]
Wang, W. [5 ]
Xu, C. [6 ]
Chen, R. [2 ]
Xia, X. [2 ]
机构：
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Med Oncol, Wuhan, Hubei, Peoples R China
[2] Geneplus Beijing, Beijing, Peoples R China
[3] Jiangsu Prov Hosp, Oncol, Nanjing, Jiangsu, Peoples R China
[4] Nan Jing Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China
[5] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
[6] Fujian Canc Hosp, Fuzhou, Fujian, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
T790M; EGFR-TKIs therapy; next generation sequencing (NGS);
D O I：
10.1016/j.jtho.2018.08.583
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-27
引用
收藏
页码：S470 / S470
页数：1
相关论文
共 50 条
  • [31] EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation
    Yamada, Teppei
    Azuma, Koichi
    Muta, Emi
    Kim, Jintaek
    Sugawara, Shunichi
    Zhang, Guang Lan
    Matsueda, Satoko
    Kasama-Kawaguchi, Yuri
    Yamashita, Yuichi
    Yamashita, Takuto
    Nishio, Kazuto
    Itoh, Kyogo
    Hoshino, Tomoaki
    Sasada, Tetsuro
    PLOS ONE, 2013, 8 (11):
  • [32] Loss of T790M Mutation is Associated with Early Progression to Osimertinib in Chinese Advanced NSCLC Patients Harboring EGFR T790M
    Zhao, S.
    Jiang, T.
    Li, X.
    Zhao, C.
    Su, C.
    Ren, S.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S410 - S410
  • [33] A Phase II Trial of Anlotinib Plus Osimertinib in Advanced NSCLC with EGFR T790M Mutation After Failure of Prior EGFR TKIs
    Jiang, R.
    Wang, X.
    Wang, L.
    Huang, D.
    Ding, C.
    Wang, C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S346 - S347
  • [34] Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports
    Zeng, Yue
    Feng, Yuanqing
    Fu, Guihua
    Jiang, Junlan
    Liu, Xiaohan
    Pan, Yue
    Hu, Chunhong
    Liu, Xianling
    Wu, Fang
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [35] Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
    Yen-Hsiang Huang
    Jeng-Sen Tseng
    Kuo-Hsuan Hsu
    Kun-Chieh Chen
    Kang-Yi Su
    Sung-Liang Yu
    Jeremy J. W. Chen
    Tsung-Ying Yang
    Gee-Chen Chang
    Scientific Reports, 11
  • [36] T790M detection rate after first-line combination therapy with bevacizumab and EGFR-TKIs in advanced NSCLC (TERRA Study)
    Kuo, Chih-Hsi Scott
    Su, Po-Lan
    Wei, Yu-Feng
    Ko, Jen-Chung
    Tseng, Jeng-Sen
    Su, Jian
    Chiang, Chi-Lu
    Chen, Chung-Yu
    Lin, Chien-Chung
    Wang, Chin-Chou
    Ho, Chao-Chi
    Chang, Huang-Chih
    Hung, Jen-Yu
    AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (07): : 3100 - +
  • [37] Reduced sensitivity for EGFR T790M mutations using the Idylla EGFR Mutation Test
    Lee, Eric
    Jones, Victoria
    Topkas, Eleni
    Harraway, James
    JOURNAL OF CLINICAL PATHOLOGY, 2021, 74 (01) : 43 - 47
  • [38] Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer
    Baglivo, Sara
    Ludovini, Vienna
    Sidoni, Angelo
    Metro, Giulio
    Ricciuti, Biagio
    Siggillino, Annamaria
    Rebonato, Alberto
    Messina, Salvatore
    Crino, Lucio
    Chiari, Rita
    MAYO CLINIC PROCEEDINGS, 2017, 92 (08) : 1304 - 1311
  • [39] A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs
    Lu, S.
    Zhang, Y.
    Zhang, G.
    Zhou, J.
    Cang, S.
    Cheng, Y.
    Wu, G.
    Cao, P.
    Lv, D.
    Jian, H.
    Chen, C.
    Jin, X.
    Tian, P.
    Wang, K.
    Jiang, G.
    Chen, G.
    Chen, Q.
    Zhao, H.
    Ding, C.
    Guo, R.
    Sun, G.
    Wang, B.
    Jiang, L.
    Liu, Z.
    Fang, J.
    Yang, J.
    Zhuang, W.
    Liu, Y.
    Zhang, J.
    Pan, Y.
    Chen, J.
    Yu, Q.
    Zhao, M.
    Cui, J.
    Li, D.
    Yi, T.
    Yu, Z.
    Yang, Y.
    Zhang, Y.
    Zhi, X.
    Huang, Y.
    Wu, R.
    Chen, L.
    Zang, A.
    Cao, L.
    Li, Q.
    Li, X.
    Song, Y.
    Wang, D.
    Zhang, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S469 - S469
  • [40] Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer without harboring EGFR T790M mutation
    Lian, Zengzhi
    Du, Wenwen
    Zhang, Yang
    Fu, Yulong
    Liu, Ting
    Wang, Anqi
    Cai, Tingting
    Zhu, Jianjie
    Zeng, Yuanyuan
    Liu, Zeyi
    Huang, Jian-an
    THORACIC CANCER, 2020, 11 (07) : 1934 - 1943
12345